摘要
目的 研究瑞舒伐他汀对冠心病患者LDL-C/HDL-C、ApoA1/ApoB100和hs-CRP的影响及其安全性.方法 入选100例冠心病患者,随机分为辛伐他汀组（40 mg/d）48例和瑞舒伐他汀组（10 mg/d）52例,用药前和用药后8周末分别监测血清中的血脂参数、LDL-C/HDL-C、ApoA1/ApoB100和hs-CRP的浓度及肝肾功能,比较两组治疗前、后及两组治疗后各指标的差异.结果 ①两组治疗前后比较,血脂水平、LDL-C/HDL-C、ApoA1/ApoB100和hs-CRP均有明显变化（P＜0.05）,差异有统计学意义.②瑞舒伐他汀组治疗后的LDL-C、HDL-C、ApoBl00、LDL-C/HDL-C、ApoA1/ApoB100差异较辛伐他汀组明显（P＜0.05）,且有统计学意义.③两组不良反应少,安全性好.结论 对于冠心病患者,瑞舒伐他汀有更好的调脂疗效,且安全性与辛伐他汀相似.
Objective To investigate the influence and safety of rosuvastatin on LDL-C/HDL-C ,ApoA1, ApoB100 and hs-CRP in the patients with coronary heart disease. Methods One hundred CHD patients were enrolled and randomly divided into groups of simvastatin （40 rag/d） forty-eight and rosuvastatin （10 mg/d） fifty- two. The levels of the blood-lipid parameters, LDL-C/HDL-C,ApoA1/ApoB100, hs-CRP and the function of liver and kidney were determined before and after the end of the eighth weeks with these medicines in all patient, compared these values around and after treatment, and to estimate the effectiveness and safety of rosuvastatin. Results （1）The variation of the blood-lipid parameters, LDL-C/HDL-C, ApoA1/ApoB100 and hs-CRP was obvi- ous before and after treatment in two groups（P〈0.05 ）, and the difference was significant in statistics. （2）The varia- tion of the LDL-C, HDL-C, LDL-C/HDL-C, ApoA1/ApoB100 and hs-CRP after treatment in the group of ro- suvastatin were more prominent than simvastatin （P〈0.05）, and the difference was significant in statistics. （3）The adverse reaction in two groups was fewness and the security was fine. Conclusion The effectiveness of regulating blood lipid with rosuvastatin is better than simvastatin, but the security is similar.
出处
《中国心血管病研究》
CAS
2011年第2期102-105,共4页
Chinese Journal of Cardiovascular Research
